Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

21

Revenue 2017

41

Revenue 2017

Xarelto

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Xarelto was produced by Bayer and Johnson & Johnson.

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

Daiichi Sankyo gets EU OK for Lixiana anticoagulant It is competing in the NOAC category against two other drugs in that class - Pfizer's Eliquis (apixaban) and Bayer/Johnson &Johnson's Xarelto (rivaroxaban) - as well as Boehringer Ingelheim's ... Pradaxa and Eliquis are given twice-daily, while Xarelto

Novel anticoagulant antidotes prove their worth

Novel anticoagulant antidotes prove their worth Boehringer has already submitted idarucizumab for approval in the US, EU and Canada, taking the lead among companies developing antidotes for NOACs, which also include Factor Xa inhibitors Xarelto (rivaroxaban) from ... Earlier trials have also shown

Eylea growth closes the gap with Lucentis

Eylea growth closes the gap with Lucentis Combined sales of Bayer's five growth products - Eylea, pulmonary hypertension drug Adempas (riociguat), anticoagulant Xarelto (rivaroxaban) and cancer therapies Stivarga (regorafenib) and Xofigo (radium Ra 223 dichloride) - came in at ... Xarelto grew

BMS shines in Q1, but Abilify generics cast a long shadow

BMS shines in Q1, but Abilify generics cast a long shadow The acceleration in Eliquis sales comes despite increasingly fierce competition among the novel oral anticoagulant (NOAC) class, which includes Johnson &Johnson/Bayer's Xarelto (rivaroxaban) and Boehringer Ingelheim's Pradaxa (dabigatran)

Boehringer steals lead among NOACs with Pradaxa antidote

Boehringer steals lead among NOACs with Pradaxa antidote Thrombin inhibitor Pradaxa and other NOACs on the market - notably the Factor Xa inhibitors Xarelto (rivaroxaban) from Bayer and Johnson &Johnson (J&J), Pfizer/Bristol-Myers Squibb's Eliquis (apixaban) and ... If idarucizumab makes speedy progress to

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...